Sugi Predict

Sugi Predict / Targets / GCGR

GCGR

Glucagon receptor · P47871 · GCGR on Sugi Atlas →

63,567 patent compounds predicted against GCGR, 33,611 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Mk-0893 Mk-0893 (SCHEMBL675777) 1.00 20/20
SCHEMBL675778 SCHEMBL675778 0.86 20/20
SCHEMBL719587 SCHEMBL719587 0.69 20/20
SCHEMBL526996 SCHEMBL526996 0.56 19/20
SCHEMBL105891 SCHEMBL105891 1.00 18/20
SCHEMBL719209 SCHEMBL719209 0.59 18/20
SCHEMBL716441 SCHEMBL716441 0.53 18/20
SCHEMBL719157 SCHEMBL719157 0.51 18/20
SCHEMBL67603 SCHEMBL67603 0.60 16/20
SCHEMBL719164 SCHEMBL719164 0.55 16/20
SCHEMBL66986 SCHEMBL66986 0.60 15/20
SCHEMBL68165 SCHEMBL68165 0.60 15/20
SCHEMBL84724 SCHEMBL84724 0.60 15/20
Sb-203580 Sb-203580 (SCHEMBL95208) 0.75 14/20
Sb-203580 Sb-203580 (SCHEMBL146399) 0.75 14/20
Sb-203580 Sb-203580 (SCHEMBL220990) 0.75 14/20
SCHEMBL67984 SCHEMBL67984 0.72 14/20
SCHEMBL69095 SCHEMBL69095 0.67 14/20
SCHEMBL67192 SCHEMBL67192 0.64 14/20
Sb-202190 Sb-202190 (SCHEMBL158854) 1.00 13/20

Clinical trials — most relevant to GCGR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) PHASE4NOT_YET_RECRUITING
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon PHASE4COMPLETED
A Research Study of VCT220 in Adult Chinese Participants With Obesity PHASE3ACTIVE_NOT_RECRUITING
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects PHASE3RECRUITING
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion PHASE3COMPLETED
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility PHASE3UNKNOWN
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS PHASE3COMPLETED
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY) PHASE2/PHASE3COMPLETED
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity PHASE2RECRUITING
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes PHASE2COMPLETED
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight PHASE2NOT_YET_RECRUITING
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment PHASE1/PHASE2RECRUITING
Pasireotide in Hyperinsulinemic Hypoglycemia PHASE2WITHDRAWN
Bioequivalence Study of GZR18 Injection Before and After CMC Change PHASE1RECRUITING
A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624 PHASE1COMPLETED
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus PHASE1COMPLETED
Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration PHASE1COMPLETED
Hepatic Metabolic Changes in Response to Glucagon Infusion nanCOMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance nanUNKNOWN
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans. nanCOMPLETED
Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores nanNOT_YET_RECRUITING
Gut Microbiota and Modulation of Liver Damage in NAFLD nanCOMPLETED
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation nanCOMPLETED
Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic Steatosis nanCOMPLETED
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention nanNOT_YET_RECRUITING
Hepatic Histology and Metabolism Following Total Pancreatectomy and Pancreaticoduodenectomy nanUNKNOWN
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. nanRECRUITING
Effects of Liraglutide on Body Surface Gastric Mapping nanCOMPLETED
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD nanRECRUITING
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a GCGR binder may also engage these)

ProteinNameSimilarity
Q61606 — 1.000 Q61606 →
P43219 — 1.000 P43219 →
O35659 — 1.000 O35659 →
A0A2Z2U4G9 — 1.000 A0A2Z2U4G9 →
Q0P543 — 1.000 Q0P543 →
GIPR Gastric inhibitory polypeptide receptor 1.000 landscape →
P34999 — 1.000 P34999 →
Q28992 — 1.000 Q28992 →
P43218 — 1.000 P43218 →
GLP1R Glucagon-like peptide 1 receptor 0.998 landscape →
O46502 — 0.998 O46502 →
Q5FWI2 — 0.998 Q5FWI2 →
P30083 — 0.998 P30083 →
Q5IXF8 — 0.997 Q5IXF8 →
GHRHR Growth hormone-releasing hormone receptor 0.997 landscape →
P97751 — 0.996 P97751 →
P30082 — 0.996 P30082 →
P32301 — 0.996 P32301 →
VIPR1 Vasoactive intestinal polypeptide receptor 1 0.995 landscape →
Q9Z0W0 — 0.995 Q9Z0W0 →
O95838 — 0.995 O95838 →
Q02644 — 0.994 Q02644 →
P32082 — 0.994 P32082 →
Q1LZF7 — 0.994 Q1LZF7 →
P23811 — 0.993 P23811 →
VIPR2 Vasoactive intestinal polypeptide receptor 2 0.993 landscape →
P25117 — 0.992 P25117 →
SCTR Secretin receptor 0.990 landscape →
Q5RAQ1 — 0.990 Q5RAQ1 →
P41588 — 0.990 P41588 →